AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB

AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB

REVISED RELEASE first issued July 28, 2021

VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) — AREV NANOTEC BRANDS INC. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Firm”) pronounces that the Firm has entered right into a collaborative growth settlement with Voynich Biosciences, Inc. (“Voynich”) that additional advances AREV’s flagship initiative, the next-generation Prepared-to-Use Therapeutic Meals (“RUTF”), SUS-TAINN™. Voynich is an early-stage, privately-held, phytomedicinal discovery firm headquartered in Hawaii.

AREV, in collaboration with Voynich, will probably be pursuing definitive partnerships with authorities and non-governmental organizations to make sure the profitable supply of SUS-TAINN to probably the most severely affected areas. The RUTF market was valued at USD $363.72 Million in 2019 and is projected to achieve USD $807.89 Million by 2027, rising at a CAGR of 10.5% from 2020 to 2027 in line with a latest UNICEF report on RUTFs. The collaborative settlement between AREV and Voynich enhances an current cooperative effort for tangible innovation in combating international meals insecurity and dietary deficits resulting in Extreme Acute Malnutrition (“SAM”) and hunger, clinically outlined as inanition, significantly amongst weak populations presenting co-morbid circumstances and co-infections.

This settlement between AREV and Voynich is meant as a primary step in formalizing a long-term growth collaboration. Whereas no new entity is created, the settlement establishes a administration committee of equal numbers of nominees from every firm to make selections for the collaboration. Every firm additionally commits to offering equal assets to the enterprise. AREV has contributed USD $50,000 and Voynich has supplied equal worth in form. The businesses have dedicated to barter in good religion to enter right into a long run and extra substantive collaboration but when they’re unable to achieve agreed phrases, this settlement sunsets with every social gathering departing the collaboration in a negotiated method and with equal worth, if any, from their growth work collectively.

UNICEF procures an estimated 75% to 80% of the worldwide demand for RUTFs, accepted by UNICEF to deal with 3.5 million youngsters. Regardless of the high-volume demand by UNICEF, the company nonetheless solely covers 25% of the worldwide estimated variety of youngsters affected by malnutrition. RUTFs which might be procured by governments, non-governmental organizations (NGOs) and United Nations (UN) businesses cowl a further 5 to 10%. Consequently, roughly 65 to 70% of the youngsters of the world affected by extreme losing, don’t have any entry to therapeutics. In flip, a major variety of youngsters underneath age 5 affected by SAM have been handled with RUTFs. RUTFs which might be procured by governments, non-governmental organizations, and United Nations businesses cowl a further 5 to 10%. Consequently, roughly 65 to 70% of the youngsters in useful resource poor settings are weak to extreme losing.

Mike Withrow, CEO of AREV, commented, “The experience of each Dr. Noller and Dr. van Breemen on this collaboration with Voynich permits the Firm to speed up its entry to market all through AREV’s growth pipeline. We sit up for Dr. van Breemen becoming a member of Dr. Noller on the AREV Scientific Advisory Board (SAB), which might enormously improve the Firm’s present capacities.” Mr. Withrow continued, “This collaboration strengthens AREV’s analysis and growth on its flagship product, SUS-TAINN, which is positioned to develop into a scientific intervention disrupting the stagnant therapeutic market in treating extreme acute malnutrition or SAM, which is characterised by extreme losing, often known as marasmus, kwashiorkor, and marasmus kwashiorkor, epithelial delamination, enteropathy, and reasonable acute malnutrition or MAM, that may account for an estimated $800 million by 2027.” The World Well being Group (WHO) pointers suggest the usage of RUTFs within the Updates on the Administration of Extreme Acute MALNUTRITION in Infants and Kids.

Information by The College of Cincinnati and Florida Worldwide College and the College of Southern California introduced on the 11th Worldwide AIDS Society Convention on HIV Science (“IAS 2021”) supplied validation of the scientific premise of AREV’s SUS-TAINN RUTF which demonstrates definitive correlations of malnutrition and antiviral resistance and illness development in numerous grownup and pediatric populations. Along with the scientific validation on the IAS 2021 convention, the AREV-Voynich lead collaborative therapeutic, SUS-TAINN’s scientific premise is supported by a March 2021 report printed by UNICEF. This scientific proof suggests a rise in illness development in affected person populations that lack entry to therapeutic dietary help which additional serves to scale back the effectiveness of any remedy routine.

“SUS-TAINN is differentiated from different RUTFs presently obtainable available in the market because it addresses the scientific disparities in probably the most weak populations by specializing in the mechanisms of motion clinically recognized by inanition”, acknowledged Dr. Jay S. Noller, Founder and Chief Govt Officer of Voynich Biosciences. Dr. Noller has been a pioneer within the agricultural sector, offering greater than 20 years of management at OSU, extending by a number of meals commodity enterprises on a world foundation reaching packages at over 40 establishments. Dr. Noller serves on AREV’s SAB and is a member of the Crop Science Society of America, Infectious Illness Society of America, and Worldwide AIDS Society. Additionally main Voynich is Founder and Chief Scientific Officer Richard van Breemen, PhD, the Linus Pauling Endowed Chair of Pharmaceutical Sciences and former Director of the Linus Pauling Institute at OSU. Dr. van Breemen, with a Ph.D. in Pharmacology and Experimental Therapeutics, co-founded the UIC/NIH Middle for Botanical Dietary Dietary supplements Analysis.

SUS-TAINN’s formulation comprises very important dietary components to make sure circumstances reminiscent of malnutrition might be minimized and that antiviral therapies might be administered with effectiveness. SUS-TAINN will probably be extremely value efficient “per unit” because of superior effectivity, lighter than all present aggressive product choices and thus more cost effective to move. The curiosity in non-peanut primarily based RUTFs is growing, significantly from international locations the place peanuts are usually not a staple meals in native diets. To extend the remedy of severely wasted youngsters that haven’t had entry to remedy, UNICEF has inspired the validation and entry to various RUTF formulations reminiscent of SUS-TAINN.

For additional info, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For extra info go to arevlifesciences.com

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV NanoTec Manufacturers Inc.
AREV is an early-stage life science discovery enterprise devoted to delivering options to public well being by discovery, collaborations within the life science business, and pathogen remediation. AREV is invested in industrial improvements in phytomedicinal discoveries of small molecule antivirals and for associated uncared for continual co-morbidities and improvements human vitamin together with the late-stage growth of a Prepared-to-Use Therapeutic Meals (RUTF) for Extreme Acute Malnutrition (SAM) and an Enteral Formulation concentrating on the long-term results of continual an infection. AREV is devoted to designing and delivering innovation in rational drug design, pushed by presenting international epidemiological traits of a number of challenges to worldwide human and animal well being. AREV is a member of each BIOTECanada and The Biotechnology Innovation Group (BIO).

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION
Neither the Canadian Securities Alternate nor its Regulation Companies Supplier (as that time period is outlined in insurance policies of the CSE) accepts duty for the adequacy or accuracy of this launch. This information launch could embody forward-looking statements which might be topic to dangers and uncertainties. All statements inside, aside from statements of historic truth, are to be thought-about ahead trying. Though the Firm believes the expectations expressed in such ahead trying statements are primarily based on cheap assumptions, such statements are usually not ensures of future efficiency and precise outcomes or developments could differ materially from these in forward-looking statements. Elements that would trigger precise outcomes to vary materially from these in forward-looking statements embody market costs, exploitation and exploration successes, and continued availability of capital and financing, and basic financial, market or enterprise circumstances. There might be no assurances that such statements will show correct and, due to this fact, readers are suggested to depend on their very own analysis of such uncertainties. We don’t assume any obligation to replace any forward-looking statements besides as required underneath the relevant legal guidelines. This press launch comprises forward-looking statements. Using any of the phrases “anticipate”, “proceed”, “estimate”, “anticipate”, “could”, “will”, “mission”, “ought to”, “imagine” and comparable expressions are supposed to determine forward-looking statements. Though the Firm believes that the expectations and assumptions on which the forward-looking statements are primarily based are cheap, undue reliance shouldn’t be positioned on the forward-looking statements as a result of the Firm can provide no assurance that they’ll show to be right. Since forward-looking statements deal with future occasions and circumstances, by their very nature they contain inherent dangers and uncertainties. These statements converse solely as of the date of this press launch. Precise outcomes might differ materially from these presently anticipated because of various elements and dangers varied danger elements mentioned within the Firm’s Administration’s Dialogue and Evaluation underneath the Firm’s profile on www.sedar.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

three + 7 =